

## **SYMPHONY MEDICAL CHANGES NAME TO CARDIOPOLYMERS, INC.**

**Laguna Hills, CA, July 22, 2009** – Symphony Medical, Inc., a development-stage company focused on novel biopolymer implant therapies to treat cardiac abnormalities, announced today that it has changed the name of the corporation to CardioPolymers, Inc.

CardioPolymers, Inc. Chief Executive Officer Raymond W. Cohen said, "The name change, which is effective immediately, better reflects our focus on employing natural biocompatible polymer implants to treat cardiac patients – specifically, congestive heart failure patients with an enlarged left ventricle."

CardioPolymers is currently sponsoring a human clinical study of its patented flagship technology Algisyl-LVR<sup>®</sup> at world-class centers in Europe, including the German Heart Center in Munich where the first three patients were successfully treated.

[Algisyl-LVR](#) is an implantable medical device under clinical development intended to prevent or reverse the progression of congestive heart failure in patients with dilated cardiomyopathy, a condition in which the heart becomes weakened and enlarged, and cannot pump blood efficiently. The procedure involves injecting a proprietary biopolymer directly into strategic locations of the heart's left ventricle wall. As it is injected, the biopolymer thickens and forms firm, gel-like structures that remain in the heart muscle as permanent implants. These implants act to re-shape the heart, reduce the size of the dilated left ventricle and thicken the damaged wall of the heart, thus returning the heart to a healthier form that facilitates improved cardiac function and performance.

### **About CardioPolymers, Inc.**

CardioPolymers, Inc., a Delaware Corporation (*formerly known as Symphony Medical*) was founded in 2003 and is headquartered in Orange County, California. The Company is privately held and backed by venture investors Johnson & Johnson, Domain Associates, Morgenthaler Ventures, Triathlon Medical Ventures and Fjord Ventures. The development stage company is developing proprietary biotherapeutic products and tools to address the unmet clinical needs of millions of patients suffering from cardiac disorders.

For more information on CardioPolymers, Inc. please visit our website at [www.symphonymed.com](http://www.symphonymed.com)

Contact:

Matt Clawson  
Allen & Caron Inc  
949-474-4300  
[matt@allencaron.com](mailto:matt@allencaron.com)

7/22/2009